Symetryx Corp insider trades: NeuBase Therapeutics (NBSE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Symetryx Corp reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 18, 2023 | NBSE | ↓ Sell | 282,445 | $1.33 | $376K | Direct | Sep 18, 2023 (0d) |
| Sep 11, 2023 | NBSE | ↓ Sell | 207,075 | $1.63 | $337K | Direct | Sep 11, 2023 (0d) |
| Sep 1, 2023 | NBSE | ↑ Buy | 61,076 | $0.98 | $60K | Direct | Sep 7, 2023 (6d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Symetryx Corp's insider trades
Symetryx Corp is a 10% owner of NeuBase Therapeutics (NBSE). Since Sep 1, 2023, it has reported 1 open-market purchase worth $60K and 2 sales worth $712K on SEC Form 4. There have been no open-market trades in the last 12 months.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBSE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.